Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech's blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Diagnostic & Testing Substances Manufacturers
- Sub-Industry: N/A
- Symbol: NASDAQ:TRIB
- CUSIP: N/A
- Web: www.trinitybiotech.com
Capitalization:- Market Cap: $125.68 million
- Outstanding Shares: 21,847,000
Average Prices:- 50 Day Moving Avg: $5.76
- 200 Day Moving Avg: $5.79
- 52 Week Range: $5.11 - $13.68
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 30.71
- P/E Growth: 1.35
Sales & Book Value:- Annual Revenue: $98.79 million
- Price / Sales: 1.15
- Book Value: $4.89 per share
- Price / Book: 1.07
Profitability:- EBIDTA: $7.39 million
- Net Margins: -100.45%
- Return on Equity: 5.54%
- Return on Assets: 2.70%
Debt:- Debt-to-Equity Ratio: 0.89%
- Current Ratio: 5.33%
- Quick Ratio: 3.88%
Misc:- Average Volume: 46,942 shs.
- Beta: 1.3
- Short Ratio: 11.75
Frequently Asked Questions for Trinity Biotech PLC (NASDAQ:TRIB)
What is Trinity Biotech PLC's stock symbol?
Trinity Biotech PLC trades on the NASDAQ under the ticker symbol "TRIB."
How were Trinity Biotech PLC's earnings last quarter?
Trinity Biotech PLC (NASDAQ:TRIB) posted its earnings results on Thursday, July, 20th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by $0.03. The firm earned $25.45 million during the quarter, compared to the consensus estimate of $24.83 million. Trinity Biotech PLC had a negative net margin of 100.45% and a positive return on equity of 5.54%. View Trinity Biotech PLC's Earnings History.
When will Trinity Biotech PLC make its next earnings announcement?
Who are some of Trinity Biotech PLC's key competitors?
Some companies that are related to Trinity Biotech PLC include Curis (CRIS), DURECT Corporation (DRRX), Advaxis (ADXS), Pharming Group (PHGUF), TOCAGEN INC (TOCA), Aratana Therapeutics (PETX), Catalyst Pharmaceuticals (CPRX), Voyager Therapeutics (VYGR), Enzymotec (ENZY), UROGEN PHARMA (URGN), ObsEva SA (OBSV), Ardelyx (ARDX), uniQure N.V. (QURE), Fortress Biotech (FBIO), Organovo Holdings (ONVO), Immune Design Corp. (IMDZ), Helius Medical Technologies (HSDT) and Chimerix (CMRX).
Who are Trinity Biotech PLC's key executives?
Trinity Biotech PLC's management team includes the folowing people:
- Ronan O'Caoimh, Executive Chairman of the Board
- Kevin Tansley, Chief Financial Officer, Secretary
- Rory Nealon, Chief Operating Officer, Executive Director
- Eric Brouwer Ph.D., Chief Scientific Officer, and Vice President Cardiac
- James Walsh Ph.D., Executive Director
- Clinton H. Severson, Non-Executive Director
- Denis R. Burger Ph.D., Senior Non-Executive Independent Director
- Peter Coyne, Non-Executive Independent Director
- James D. Merselis, Non-Executive Independent Director
Who owns Trinity Biotech PLC stock?
Trinity Biotech PLC's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Paradice Investment Management LLC (7.50%), Heartland Advisors Inc. (7.17%), Janus Henderson Group PLC (6.47%), Lapides Asset Management LLC (5.90%),
LAPIDES ASSET MANAGEMENT, LLC
(5.00%) and Boston Partners (5.33%). View Institutional Ownership Trends for Trinity Biotech PLC.
Who sold Trinity Biotech PLC stock? Who is selling Trinity Biotech PLC stock?
Trinity Biotech PLC's stock was sold by a variety of institutional investors in the last quarter, including US Bancorp DE, Boston Partners, Royce & Associates LP, JPMorgan Chase & Co., Stonepine Capital Management LLC, GRT Capital Partners L.L.C., Arrowstreet Capital Limited Partnership and Wedbush Securities Inc.. View Insider Buying and Selling for Trinity Biotech PLC.
Who bought Trinity Biotech PLC stock? Who is buying Trinity Biotech PLC stock?
Trinity Biotech PLC's stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Senvest Management LLC, Hunter Associates Investment Management LLC, Russell Investments Group Ltd., Heartland Advisors Inc., Paradice Investment Management LLC, Lapides Asset Management LLC and Teton Advisors Inc.. View Insider Buying and Selling for Trinity Biotech PLC.
How do I buy Trinity Biotech PLC stock?
Shares of Trinity Biotech PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trinity Biotech PLC's stock price today?
One share of Trinity Biotech PLC stock can currently be purchased for approximately $5.22.
MarketBeat Community Rating for Trinity Biotech PLC (NASDAQ TRIB)MarketBeat's community ratings are surveys of what our community members think about Trinity Biotech PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Trinity Biotech PLC (NASDAQ:TRIB) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating |
| Consensus Rating: | Hold (Score: 2.00) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Trinity Biotech PLC (NASDAQ:TRIB)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/5/2016 | Stephens | Downgrade | Overweight -> Equal Weight | | N/A |  |
| 4/21/2016 | Roth Capital | Reiterated Rating | Buy | | N/A | |
| 10/23/2015 | Craig Hallum | Downgrade | Buy -> Hold | $24.00 -> $14.00 | N/A | |
| 9/3/2015 | Raymond James Financial, Inc. | Initiated Coverage | Outperform | $20.00 | N/A | |
(Data available from 8/18/2015 forward)
Earnings History for Trinity Biotech PLC (NASDAQ:TRIB)Earnings History by Quarter for Trinity Biotech PLC (NASDAQ TRIB)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/23/2017 | | $0.07 | | | | | N/A | |
| 7/20/2017 | 6/30/2017 | $0.06 | $0.03 | $24.83 million | $25.45 million | View | N/A | |
| 4/27/2017 | 3/31/2017 | $0.03 | $0.01 | $24.24 million | $23.54 million | View | N/A | |
| 10/25/2016 | Q3 | $0.07 | $0.07 | $26.50 million | $26.10 million | View | Listen | |
| 7/21/2016 | Q2 | $0.06 | $0.09 | $24.30 million | $26.30 million | View | Listen | |
| 4/19/2016 | Q1 | $0.08 | $0.06 | $24.34 million | $23.52 million | View | Listen | |
| 3/3/2016 | Q4 | $0.09 | $0.29 | $251.00 million | $271.20 million | View | N/A | |
| 10/22/2015 | Q3 | $0.09 | $0.10 | $25.40 million | $27.20 million | View | Listen | |
| 7/28/2015 | Q2 | $0.14 | $0.07 | $26.09 million | $24.26 million | View | Listen | |
| 4/30/2015 | Q115 | $0.17 | $0.17 | $25.93 million | $25.20 million | View | N/A | |
| 3/3/2015 | Q414 | $0.18 | $0.18 | $27.30 million | $26.70 million | View | N/A | |
| 10/23/2014 | Q114 | $0.20 | $0.19 | $27.30 million | $27.20 million | View | Listen | |
| 7/29/2014 | Q413 | $0.20 | $0.18 | $27.00 million | $26.00 million | View | N/A | |
| 4/29/2014 | | $0.19 | $0.18 | $25.48 million | $25.03 million | View | N/A | |
| 3/4/2014 | Q4 | $0.21 | $0.20 | | | View | N/A | |
| 10/17/2013 | Q313 | $0.21 | $0.21 | $24.68 million | $24.10 million | View | N/A | |
| 7/30/2013 | Q2 2013 | $0.20 | $0.21 | $22.03 million | $21.30 million | View | N/A | |
| 3/5/2013 | Q4 2012 | $0.21 | $0.20 | $21.84 million | $20.80 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Trinity Biotech PLC (NASDAQ:TRIB)2017 EPS Consensus Estimate: $0.26
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $0.04 | $0.04 | $0.04 |
| Q2 2017 | 1 | $0.06 | $0.06 | $0.06 |
| Q3 2017 | 1 | $0.08 | $0.08 | $0.08 |
| Q4 2017 | 1 | $0.08 | $0.08 | $0.08 |
(Data provided by Zacks Investment Research)
Dividend History by Quarter for Trinity Biotech PLC (NASDAQ TRIB)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/23/2014 | annual | $0.22 | 3.72% | 6/6/2014 | 6/10/2014 | 7/1/2014 |
(Data available from 1/1/2013 forward)
Insider Trading History for Trinity Biotech PLC (NASDAQ:TRIB)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Trinity Biotech PLC (NASDAQ:TRIB)
Latest Headlines for Trinity Biotech PLC (NASDAQ:TRIB)
| Source: |
|
| Date | Headline |
|---|
 | INVESTOR ALERT: Kirby McInerney LLP Commences Investigation on Behalf of Trinity Biotech plc Investors
finance.yahoo.com - August 11 at 8:57 AM |
| Trinity Biotech Plc :TRIB-US: Earnings Analysis: Q2, 2017 By the Numbers : July 26, 2017
finance.yahoo.com - July 27 at 8:37 AM |
 | Trinity Biotech PLC (TRIB) Issues Quarterly Earnings Results
www.americanbankingnews.com - July 21 at 11:05 AM |
 | Investor Network: Trinity Biotech Plc Sponsored ADR to Host Earnings Call
www.baystreet.ca - July 21 at 8:01 AM |
| Investor Network: Trinity Biotech Plc Sponsored ADR to Host Earnings Call
www.baystreet.ca - July 21 at 8:01 AM |
| Edited Transcript of TRIB earnings conference call or presentation 20-Jul-17 3:00pm GMT
finance.yahoo.com - July 21 at 8:01 AM |
| Edited Transcript of TRIB earnings conference call or presentation 20-Jul-17 3:00pm GMT
finance.yahoo.com - July 21 at 8:01 AM |
| Head-To-Head Survey: Trinity Biotech PLC (TRIB) & DBV Technologies (DBVT)
www.americanbankingnews.com - July 20 at 9:16 AM |
| Trinity Biotech PLC (NASDAQ:TRIB) vs. DBV Technologies (DBVT) Head-To-Head Survey
www.americanbankingnews.com - July 20 at 9:15 AM |
| Trinity Biotech Announces Results for Q2, 2017
finance.yahoo.com - July 20 at 8:51 AM |
| Contrasting Trinity Biotech PLC (TRIB) & DBV Technologies (DBVT)
www.americanbankingnews.com - July 18 at 12:27 AM |
| Trinity Biotech PLC (TRIB) Set to Announce Earnings on Thursday
www.americanbankingnews.com - July 13 at 10:08 PM |
| Trinity Biotech plc to Announce Second Quarter Fiscal Year 2017 Financial Results
finance.yahoo.com - July 4 at 8:10 AM |
 | Trinity Biotech plc to Announce Second Quarter Fiscal Year 2017 Financial Results
feeds.benzinga.com - July 3 at 8:29 AM |
| Trinity Biotech PLC (TRIB) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - July 2 at 4:58 PM |
| Comparing DBV Technologies (DBVT) and Trinity Biotech PLC (TRIB)
www.americanbankingnews.com - June 30 at 12:24 AM |
| Reviewing DBV Technologies (DBVT) & Trinity Biotech PLC (TRIB)
www.americanbankingnews.com - June 28 at 6:28 PM |
| Head-To-Head Contrast: DBV Technologies (DBVT) & Trinity Biotech PLC (TRIB)
www.americanbankingnews.com - June 26 at 12:10 AM |
| Meridian Bioscience (VIVO) versus Trinity Biotech plc (TRIB) Head-To-Head Comparison
www.americanbankingnews.com - June 9 at 8:57 AM |
| Trinity Biotech plc (TRIB) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - June 2 at 11:06 PM |
| Harwood Feffer LLP Announces Investigation of Trinity Biotech plc
finance.yahoo.com - May 22 at 7:18 PM |
| Trinity Biotech plc (TRIB) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 17 at 8:58 AM |
| Trinity Biotech plc (TRIB) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 11 at 11:56 AM |
| Trinity Biotech Plc :TRIB-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017
finance.yahoo.com - May 3 at 10:12 AM |
| Trinity Biotech Plc :TRIB-US: Earnings Analysis: Q4, 2016 By the Numbers : May 1, 2017
finance.yahoo.com - May 1 at 7:26 PM |
| Edited Transcript of TRIB earnings conference call or presentation 27-Apr-17 3:00pm GMT
finance.yahoo.com - April 28 at 11:07 PM |
| Trinity Biotech plc (TRIB) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - April 28 at 7:38 PM |
| Trinity Biotech plc (TRIB) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - April 28 at 4:50 PM |
| Somewhat Negative News Coverage Extremely Likely to Impact Trinity Biotech plc (TRIB) Stock Price
www.americanbankingnews.com - April 28 at 1:17 PM |
| Investor Network: Trinity Biotech Plc Sponsored ADR Class A to Host Earnings Call
finance.yahoo.com - April 27 at 9:54 PM |
| Trinity Biotech Announces Results for Q1, 2017
finance.yahoo.com - April 27 at 9:22 AM |
 | Form F-3/A TRINITY BIOTECH PLC
www.streetinsider.com - April 26 at 4:46 PM |
| Trinity Biotech plc (TRIB) Getting Positive News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 19 at 8:23 AM |
| Trinity Biotech plc to Announce First Quarter Fiscal Year 2017 Financial Results
feeds.benzinga.com - April 18 at 7:40 AM |
| Trinity Biotech plc (TRIB) Getting Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 15 at 12:57 PM |
| Trinity Biotech plc (TRIB) to Release Earnings on Monday
www.americanbankingnews.com - April 14 at 11:44 PM |
| Edited Transcript of TRIB earnings conference call or presentation 14-Mar-17 3:00pm GMT
finance.yahoo.com - March 15 at 12:52 AM |
 | BRIEF-Trinity Biotech quarterly EPS $0.043
www.reuters.com - March 14 at 7:50 PM |
| Trinity Biotech announces Quarter 4 and Fiscal Year 2016 Financial Results
finance.yahoo.com - March 14 at 7:50 PM |
| Q4 2016 Trinity Biotech PLC Earnings Release - Time Not Supplied
biz.yahoo.com - March 14 at 8:56 AM |
| Trinity Biotech plc (TRIB) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 13 at 11:38 AM |
 | SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Trinity Biotech plc (TRIB) - PR Newswire (press release)
www.prnewswire.com - March 2 at 12:05 AM |
| INVESTOR ALERT: Glancy Prongay & Murray Commences Investigation on Behalf of Trinity Biotech plc Investors
finance.yahoo.com - March 2 at 12:05 AM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Trinity Biotech plc (TRIB)
finance.yahoo.com - March 2 at 12:05 AM |
| Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2016 Financial Results
finance.yahoo.com - February 24 at 11:03 AM |
| Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2016 Financial Results
feeds.benzinga.com - February 24 at 8:13 AM |
 | Immunoassay Markets: Global Analysis and Opportunity Evaluation 2016 - 2020
www.marketwatch.com - January 24 at 12:17 AM |
| The Top 200 IVD Companies In Europe
finance.yahoo.com - January 16 at 8:05 PM |
 | Bragar Eagel & Squire, P.C. Is Investigating Trinity Biotech plc (TRIB) on Behalf of Stockholders and Encourages ... - Business Wire (press release)
www.businesswire.com - January 7 at 6:07 AM |
| Bragar Eagel & Squire, P.C. Is Investigating Trinity Biotech plc (TRIB) on Behalf of Stockholders and Encourages Investors to Contact the Firm
finance.yahoo.com - January 6 at 6:15 AM |
Trinity Biotech PLC (TRIB) Chart for Friday, August, 18, 2017
